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Abstract
Background: DNA repair of alkylation damage is defective in various cancers. This occurs through somatically acquired
inactivation of the MGMT gene in various cancer types, including breast cancers. In addition to MGMT, the two E. coli AlkB
homologs ALKBH2 and ALKBH3 have also been linked to direct reversal of alkylation damage. However, it is currently
unknown whether ALKBH2 or ALKBH3 are found inactivated in cancer.
Methods: Methylome datasets (GSE52865, GSE20713, GSE69914), available through Omnibus, were used to determine
whether ALKBH2 or ALKBH3 are found inactivated by CpG promoter methylation. TCGA dataset enabled us to then
assess the impact of CpG promoter methylation on mRNA expression for both ALKBH2 and ALKBH3. DNA
methylation analysis for the ALKBH3 promoter region was carried out by pyrosequencing (PyroMark Q24) in
265 primary breast tumours and 30 proximal normal breast tissue samples along with 8 breast-derived cell
lines. ALKBH3 mRNA and protein expression were analysed in cell lines using RT-PCR and Western blotting,
respectively. DNA alkylation damage assay was carried out in cell lines based on immunofluorescence and
confocal imaging. Data on clinical parameters and survival outcomes in patients were obtained and assessed
in relation to ALKBH3 promoter methylation.
Results: The ALKBH3 gene, but not ALKBH2, undergoes CpG promoter methylation and transcriptional silencing in
breast cancer. We developed a quantitative alkylation DNA damage assay based on immunofluorescence and confocal
imaging revealing higher levels of alkylation damage in association with epigenetic inactivation of the ALKBH3 gene
(P = 0.029). In our cohort of 265 primary breast cancer, we found 72 cases showing aberrantly high CpG promoter
methylation over the ALKBH3 promoter (27%; 72 out of 265). We further show that increasingly higher degree of ALKBH3
promoter methylation is associated with reduced breast-cancer specific survival times in patients. In this analysis, ALKBH3
promoter methylation at >20% CpG methylation was found to be statistically significantly associated with reduced
survival (HR = 2.3; P = 0.012). By thresholding at the clinically relevant CpG methylation level (>20%), we find
the incidence of ALKBH3 promoter methylation to be 5% (13 out of 265).
Conclusions: ALKBH3 is a novel addition to the catalogue of DNA repair genes found inactivated in breast
cancer. Our results underscore a link between defective alkylation repair and breast cancer which, additionally,
is found in association with poor disease outcome.
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Background
Epigenetics can be described as the study on mecha-
nisms by which changes in phenotype are established
and stably maintained following cellular divisions with-
out involving any changes in genotype. The fundamental
unit of chromatin is the nucleosome representing a short
stretch of DNA wrapped around a protein complex con-
sisting of histone variants arranged as octamers [1]. Nu-
cleosome occupancy over regulatory regions in DNA
associates with transcriptional activity as densely occupied
regions are poorly accessible to transcription factors [2].
The degree of nucleosome occupancy, or chromatin pack-
aging, is regulated by the use of so-called epigenetic marks
of which the best studied is undoubtedly DNA methyla-
tion involving the addition of methyl groups to the 5-
position on cytosine bases (5-meC) where cytosine is
followed by guanine, i.e. so-called CpG sites [3]. Methyl-
Binding Domain-containing proteins recognize and bind
to methylated CpGs and recruit histone modifiers to me-
diate or maintain repressed chromatin structure [3].
In cancer cells, the epigenome is frequently disrupted -
characterized by global loss in repressive marks and local-
ized modifications over regulatory elements [4]. It is now
known that genes functionally involved in shaping the epi-
genome of human cells are recurrently mutated in breast
cancer and various other cancers, e.g. MLL3, MLL2,
ARID1A and SETD2 [5]. The discoveries of recurrent mu-
tations in epigenetic genes provided a convincing link be-
tween disruptions in the epigenome and the development
of cancer. In addition to this, earlier observations had
already established repressive epigenetic marks over regu-
latory regions of known tumor suppressor genes in cancer
cells. In breast cancer, this catalogue includes CpG pro-
moter methylation of BRCA1, RAD51C, FOXC1, RUNX3
and L3MBTL4 [6–10]. Of these, the BRCA1 gene is well
established as a cancer predisposition gene where germline
mutations are found in association with greatly increased
risk for breast and ovarian cancer [11]. Other high-risk
breast cancer susceptibility genes such as BRCA2, PALB2,
BARD1, FANCM, ATM, CHEK2 and TP53, however, are
not found epigenetically silenced [12, 13].
The onset of a subset of breast cancers is strongly tied
to defective repair of DNA double-stranded breaks by
homologous recombination [14, 15]. In recent years, sev-
eral researchers have reported loss of MGMT in breast
cancer thereby implicating defective alkylation repair in
breast cancer development [16–18]. The MGMT gene
has an important role in removing cytotoxic adducts
from O(6)-guanine in DNA [19]. Proficiency for alkyl-
ation repair is critical to protect the cell against accumu-
lation of genetic mutations. Indeed, recent cancer
genome sequencing studies have revealed a profound
impact from treatment with alkylating agent temozolo-
mide leading to a specific mutational pattern [20]. This
observation provides a solid link between alkylation
damage and the formation of genetic mutations.
Alkylating agents are by-products of normal cellular
metabolism as well as being ubiquitous in the environ-
ment [21]. In addition to MGMT, at least two other
genes are known to be involved in direct reversal of al-
kylation damage, i.e. the E. coli AlkB homologs ALKBH2
and ALKBH3 both oxidative demethylases involved in
the repair of 1-methyladenine and 3-methylcytosine [21].
It is currently unknown whether ALKBH2 or ALKBH3
undergo epigenetic silencing in cancer. In this study, we
demonstrate that the ALKBH3 gene, not ALKBH2, is
found recurrently silenced in breast cancer by epigenetic
events which, furthermore, defines a group of patients
with dramatically reduced survival.
Methods
Study cohort
DNA samples were derived from primary breast tumors
(n = 265) and adjacent normal breast tissue (n = 30). The
normal breast tissue was obtained from non-tumorous re-
gions of the breast. The DNA was previously isolated from
freshly frozen tissue following a standard protocol based
on phenol-chloroform (+proteinase K) extraction. RNA
samples were available for a subset of the tumor (n = 36)
and normal breast (n = 10) tissue samples isolated using
Tri-Reagent (Thermo Fisher Scientific). Clinical parame-
ters, including tumor size, nodal status, histological grade
along with disease-specific follow-up times were obtained
from the nationwide Icelandic Cancer Registry [22]. This
work was carried out according to permits from the Ice-
landic Data Protection Commission (2006050307) and
Bioethics Committee (VSNb2006050001/03–16). In-
formed consent (written) was obtained from all patients.
The cell lines used in this study were obtained from
the American Type Culture Collection. The cells were
cultured in DMEM (CAMA-1, MDAMB-468, MCF-7,
MCF-10A, MDAMB-231 and SKBr-3) or RPMI (HCC-
38, Bt-474) with added 10% serum (+penicillin/strepto-
mycin). DNA and RNA was extracted in parallel from
the cell lines using Qiagen’s AllPrep DNA/RNA/miRNA
Universal kit (80224; Qiagen).
DNA methylation analyses
Bisulfite conversion was carried out using the EZ-96
DNA Methylation-Gold kit from Zymo Research
(D5008). We carried out the bisulfite conversion for
16 cycles of {95 °C for 30 s and 50 °C for 1 h} to then
hold at 4 °C until samples were added to the DNA col-
umns for completing the conversion following the man-
ufacturer’s guidelines (Zymo Research).
The PyroMark Assay Design 2.0 software was used
to design primers for the analysis of ALKBH3 pro-
moter methylation. The following primer sequences
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were used: 5′-(Btn)-GTGGGATTATTAGGATTGAG
GATT-3′ (5-biotin labelled) and 5′-CTCCAACAACTCC
CAATCAC-3′. The pre-amplification PCR reaction was
carried out using a hot-start PCR polymerase (Immolase
DNA polymerase from Bioline; Bio-21,047). The PCR
conditions were as follows: 96 °C for 10 min, 45 cycles of
(96 °C for 30s, 60 °C for 30s and 72 °C for 30s) followed
by 15 min hold at 72 °C and then 4 °C. The PCR products
were then captured using streptavidin coated agarose
beads (Streptavidin Sepharose High Performance 34 μm
beads, GE Healthcare) under denaturing conditions to ob-
tain single-stranded DNA. The pyrosequencing reaction
was then carried out using the PyroMark Q24 machine
(Qiagen) and PyroMark Gold-Q24 Reagents kit (Qiagen)
using the following sequencing-primer: 5′-ACATCAAA
CACTTCCT-3′.
CpG methylation for three CpG’s were assessed (−58,
−53 and −50 bp upstream of the TSS (p1) given the
FANTOM5 promoterome database) [23]. The output
data (obtained from PyroMark Q24 sequencing reac-
tions), representing percent methylated cytosines over
each of these three CpGs, was averaged for each sample
analysed. This yielded a single measure representing a
proxy for CpG methylation levels over the ALKBH3 pro-
moter region. The statistical analysis of paired tumor
and normal breast tissue samples made use of a paired
Wilcoxon’s test using the wilcox.test function in R.
Expression analyses in normal breast tissue, tumors and
cancer cell lines
RNA was extracted from tumors and normal breast tis-
sues using Tri-Reagent (Thermo Fisher Scientific). The
RNA derived from cell lines was isolated in a simultan-
eous DNA/RNA isolation procedure using the Qiagen’s
Allprep kit (Qiagen). Reverse transcription was carried out
using High-Capacity cDNA Reverse-Transcription Kit
(Thermo Fisher Scientific). ALKBH3 expression was
quantitatively analysed by the SYBR green method using a
real-time PCR (RT-PCR) machine (Applied Biosystems
7500). HPRT1 expression was used to normalize the ex-
pression data by computing the difference in Ct as follows:
2-(ALKBH3 Ct – HPRT1 Ct). The primers used for ALKBH3
were: 5′-AGCCACGAGTGATTGACAGAG-3′ and 5′-
ACAAACAGACCCTAGATACACCT-3′, and for HPRT1:
5′- CCTGGCGTCGTGATTAGTGAT-3′ and 5′-AGACG
TTCAGTCCTGTCCATAA-3′. The Spearman’s rank test
for correlation was carried out using the cor.test function
in R to assess the association between CpG methylation
and expression.
Proteins were extracted from cell lines at 80% con-
fluency using the EBC lysis buffer and measured at
490 nm using a spectrophotometer. The samples were
denatured and electropherized using a 10% gel followed
by transfer to PVDF membrane. The primary antibody
(Millipore anti-ALKBH3 rabbit polyclonal 09–882) was
used at 1:500 dilution overnight at 4 °C followed by
washing with PBS-Tween. The secondary antibody
(Santa Cruz donkey anti-rabbit IgG-HRP, sc-2313) was
used at 1:10,000 dilution. The membrane was developed
with ECL (Pierce ECL Plus Western Blotting Substrate,
Thermo Scientific 32,132) and detected in a ImageQuant
LAS4000. The β-actin primary antibody (MAB1501R;
Millipore) was used at a dilution of 1:20,000 with sec-
ondary HRP-rabbit antibody anti-mouse IgG used at 1:
10,000 dilution (61–6020; Invitrogen).
DNA alkylation damage detection
CAMA1 and MDA-MB-468 were grown on coverslips
and fixed with freshly prepared 4% para-formaldehyde
solution for 15 min. After fixation, cells were treated
with 1.5 M HCL for 20 min, to gain access to single
stranded DNA, followed by a 2-min treatment with So-
dium Borate (pH 8.5) to neutralize the acid. After perm-
abilization (5 min, 0.2% TritonX) and 1 h of blocking
(DMEM (Gibco) with 10% FBS (Gibco)) cells were
stained with antibodies against 3-methylcytosine (3meC)
(rabbit, Active Motif, 61111) and 5-methylcytosine
(5meC) (mouse, abcam, ab10805) for 1 h at room
temperature. Both antibodies were diluted 1:250 in
blocking buffer. Next, samples were incubated with sec-
ondary antibodies, Alexa-Fluor 488 goat anti rabbit
(A11008, Thermo Fisher Scientific) and Alexa-Fluor 555
goat anti-mouse (A21422, Thermo Fisher Scientific), di-
luted in blocking buffer (1:1000) for 1 h. Nuclear DNA
was stained by DAPI (SIGMA, D9542). The DAPI stain
was added directly to the secondary antibody solution
(diluted 1:5000). After drying, the coverslips were
mounted on glass slides using Fluoroshield (SIGMA,
F6182) mounting medium.
Images were acquired using the FV1200 Olympus
inverted confocal microscope. Dual colour confocal images
were acquired with standard settings using laser lines
488 nm and 543 nm for excitation of Alexa Fluor 488 and
Alexa Fluor 568 dyes, respectively. Nuclear DAPI staining
was imaged using excitation by the 405 nm laser. For each
condition 10 images were randomly acquired with the 20X/
0.75 objective and imported into CellProfiler for down-
stream image analysis. For each data point, 400–600 nuclei
(identified by DAPI staining) were analysed for 3meC and
5meC nuclear intensity (mean integrated intensity).
The 3meC and 5meC values presented in Fig. 2d are
based on four independent staining experiments. The
Wilcoxon’s rank sum hypothesis test was used to assess
differences in 3meC and 5meC values (in R 3.1.0).
Tissue microarrays (TMAs)
Estrogen receptor (ER), progesterone receptor (PR) and
HER-2 expression were previously analysed on tumors
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by immunohistochemistry (IHC) on tissue microarrays
(TMAs) [24]. The TMAs were constructed as previously
described (Stefansson et al. 2009). Immunohistochemis-
try (IHC) was then applied using 4 μm thick TMA sec-
tions using the following anti-bodies: anti-ER (1D5;
DAKO), anti-PR (PgR 636; DAKO) and anti-HER2 (Her-
cepTest Kit; DAKO). ER and PR were scored positive
given any visible nuclear staining in more than 1% of
tumor cell nuclei. HER-2 positivity was defined as score
of 3+ according to criteria provided by the anti-body
manufacturer.
Informatics and statistical analyses
Information on CpG methylation over the promoter re-
gion of ALKBH2 and ALKBH3 was obtained from pre-
existing methylome analyses published by Stefansson et
al. (GSE52865), Dedeurwaerder et al. (GSE20713) and
Teschendorff et al. (GSE69914) available through the
Omnibus repository at NCBI’s website (www.ncbi.nlm.-
nih.gov/gds/) [7, 25, 26]. The normalized data were ex-
tracted from the SOFT formatted files using the
GEOquery package in R and analysed by comparing nor-
mal breast tissue samples and breast cancers. This was
carried out using the Student’s t-test on M–values com-
puted using Mi = log2(Bi / (1-Bi)) where B represents the
β-value coupled with the Benjamini-Hochberg adjust-
ment procedure to account for multiple hypothesis test-
ing making use of the p.adjust function in R. The
multiple hypothesis adjustment accounted for the total
number of CpGs represented on the array platform, i.e.
adjusting for the entire >450 thousand CpGs in
GSE52865 and GSE69914 and >27 thousand CpGs in
GSE20713.
DNA methylation (450 K Infinium) and RNAseq (V2)
level 3 data were downloaded from the Cancer Genome
Atlas data repository (http://cancergenome.nih.gov/)
[27]. Firstly, the analysis of differential ALKBH3 mRNA
expression levels between normal breast tissue and
breast cancers was carried out using the Wilcoxon’s rank
sum hypothesis test taking into account adjustment for
multiple hypothesis testing including the entire set of
>20 thousand genes included in the RNAseqV2 dataset.
This was carried out using the Benjamini-Hochberg
(BH) procedure through the p.adjust function in R.
Secondly, the relation between CpG methylation for each
site represented over either ALKBH2 and ALKBH3 were
studied with respect to ALKBH3 mRNA expression using
Spearman’s correlation analysis and, as before, with
genome-wide adjustment of the P-values using the BH
procedure to account for multiple hypothesis testing.
Information on epigenetic marks for the ALKBH3 pro-
moter region in variant human mammary epithelial cells
(vHMEC) was obtained from the Roadmap Epigenomics
browser (egg2.wustl.edu/roadmap/web_portal/) [28]. This
includes information on ALKBH3 expression based on
RNA sequencing and chromatin marks based on ChIP-
seq along with data on chromatin accessibility based on
DNA sequencing. Data on CpG methylation for the
vHMEC cells was derived from methylCRF computational
analysis using MeDIP-seq and MRE-seq data to infer
whole-genome 5-methylcytosine states as carried out and
provided by the Roadmap Epigenomics project [28].
Information on nucleotide positions for ALKBH3 gene
structure (introns and exons) was downloaded from
Ensembl (GRCh37 browser; HG19). Data on transcrip-
tional start site (TSS) and CpG islands were obtained
from the FANTOM5 promoterome [23]. Using the
UCSC genome browser, the chromStart/chromEnd fields
in the hg19.cpgIslandExt table provided the CpG island
positional information. The R statistical software (R
3.1.0) was then used to graphically represent the
ALKBH3 promoter with respect to the TSS, 1st Exon
and CpG island.
The association between ALKBH3 promoter methyla-
tion and subtype-specific markers was assessed using
wilcoxon’s rank sum hypothesis testing (wilcox.test in
R). The chi-squared test was used to assess the associ-
ation between tumor subtype classification, histological
grade, tumor size and nodal status (chisq.test in R). Dif-
ferences in breast cancer-specific patient survival with
respect to ALKBH3 methylation in tumor tissue was
assessed using the log-rank hypothesis test (survdiff
function in R). Cox’s proportional hazards regression
model was use for multivariate analysis of survival
(coxph function in R). The cox.zph function in R was
applied to assess the assumptions of the regression
model with respect to proportionality over time.
Results
Methylome analyses identify ALKBH3 as a target of CpG
promoter methylation in breast cancer
By making use of methylome data for breast cancers and
normal breast tissues, we specifically asked whether aber-
rant CpG methylation events are found over the promoter
region of either ALKBH2 or ALKBH3. To achieve this, we
used datasets available through Omnibus including those
published by Stefansson et al. (GSE52865), Dedeurwaerder
et al. (GSE20713) and Teschendorff et al. (GSE69914)
[7, 25, 26]. The analysis of these datasets consistently
identify aberrant CpG methylation over the ALKBH3 gene
promoter in breast cancers. Figure 1a illustrates this find-
ing where statistically significant CpG methylation events
are seen over the ALKBH3 promoter region (Padj < 0.001).
In contrast, differential methylation between breast cancer
and normal breast tissue was not identified over the pro-
moter region of ALKBH2 (Fig. 1a).
We used the Cancer Genome Atlas dataset to assess
the impact of ALKBH3 promoter methylation on mRNA
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Fig. 1 CpG methylation over the promoter region ALKBH2 and ALKBH3 in breast cancers and normal breast tissue samples. a CpG methylation states
obtained from GSE69914 over ALKBH2 (upper panel) and ALKBH3 (lower panel) in normal breast tissue samples and breast cancers in black and red,
respectively. The y-axis represents β (beta)-values (reflecting the degree of 5-cytosine methylation) for CpG’s included on the Infinium arrays located within
or proximal to the promoter region for ALKBH2 and ALKBH3 arranged on the x-axis according to nucleotide position. The dashed lines (in black) represent
the upper and lower 99% confidence intervals for the distribution of β-values in normal breast tissue samples – thus displaying the “normal range” for each
of the CpGs analysed. Differentially methylated CpGs between breast cancers and normal breast tissues are indicated by blue asterisk marks taking into
account correction for multiple hypothesis testing including all CpGs represented on the 450 K array (Padj < 0.001). FANTOM5 regions for ALKBH2 and
ALKBH3 are shown as arrows indicating transcription start sites (TSS) where p1 represents the major TSS (while p2 and p3 are less prominently used as TSS).
Additionally, the location of UCSC defined CpG islands (CGI; strikethrough patterned boxes) and the 1st Exon for each of the two genes are labelled. UCSC
defined CpG islands from the UCSC genome table browser. b Left panel; ALKBH3 mRNA expression levels by RNA sequencing (RNAseq) obtained from the
TCGA dataset analysed with respect to normal breast tissue samples compared with breast cancers. These differences reflect generally lowered expression
levels in breast cancers compared with normal breast tissue samples. The P-value indicated in the upper-left corner was derived from Wilcoxon’s hypothesis
testing after adjusting for multiple hypotheses accounting for >20 thousand protein-coding genes represented in the RNAseq dataset (Padj = 0.018). The
right panel displays the topmost significant CpG (ranked according to the adjusted P-value), i.e. cg12046254, illustrating the relation between ALKBH3 mRNA
expression (y-axis) and CpG promoter methylation (x-axis). Again, the dashed lines (in black) represent the lower and upper 99% confidence limits for the
normal breast tissue samples – reflecting the “normal range” of 5-methylcytosine levels for this particular CpG (cg12046254). The P-value indicated in the
top-right corner, based on Spearman’s rho correlation analysis, was highly significant even after adjustment for multiple hypothesis testing
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expression levels. Firstly, these data provide additional
support for differential methylation over the ALKBH3
promoter region between normal breast tissue and tu-
mours (data not shown). Secondly, significantly lower
expression levels of ALKBH3 mRNA were seen in breast
cancers compared with normal breast tissue samples.
This finding holds statistically significant after adjusting
for multiple hypothesis testing taking into account the
entire >20 thousand protein-coding genes in the RNA-
seqV2 TCGA dataset (Wilcoxon’s rank sum test; Pad-
justed = 0.018) as shown in Fig. 1b (left panel). Thirdly,
the majority of the CpGs identified as differentially
methylated are also found significantly associated with
down-regulation of ALKBH3 mRNA levels in breast
cancers (Fig. 1b, right panel; Additional file 1). The top-
most significant CpG derived from this analysis (Spear-
man’s rho = −0.47; Padj < 0.00001) is represented by
cg12046254 shown in Fig. 1b (right panel).
Epigenetics and expression of ALKBH3 in normal breast
epithelial cells
Information on epigenetic regulation and expression of
the ALKBH3 gene in human mammary epithelial cells
(vHMEC) is displayed in Fig. 2a demonstrating tran-
scriptionally active chromatin configuration over the
promoter region. This can be seen in DNase-seq signal
peaks found upstream of the promoter and extending
into the first exon together with active histone markings,
i.e. H3 lysine 4 tri-methylation (H3K4Me3) localized
over the first exon and H3 lysine 36 tri-methylation
(H3K36Me3) over the gene body region collectively indi-
cating open chromatin and active transcription (Fig. 2a).
Notably, the H3K4Me3 activation marks are found in
the absence of repressive H3 lysine 4 mono-methylation
(H3K4me1), H3 lysine 27 tri-methylation (H3K27Me3)
and H3 lysine 9 tri-methylation (H3K9Me3) as shown in
Fig. 2a. Indeed, the expression data (RNAseq track)
shows clear signals from all ten exons of the ALKBH3
gene – the first three exons are shown in Fig. 2a.
In agreement with transcriptionally active chromatin
configuration, the ALKBH3 gene promoter region and
first exon are lacking of repressive CpG methylation
marks (DNA methyl track in Fig. 2a). The ALKBH3 pro-
moter is associated with a CpG island (spanning a region
from 43,902,254 bp to 43,902,528 bp) extending into the
first exon (Fig. 2b) and, indeed, the entire CpG island
(CGI) is found unmethylated in the vHMEC breast epi-
thelial cells. The CGI was identified from the UCSC gen-
ome table browser defined as regions of at least 200 bp
where the GC content is at least 50%. The ALKBH3 pro-
moter associated CGI was found to be 274 base pairs in
length.
We designed a DNA methylation pyrosequencing
assay to carry out CpG methylation analysis for the
ALKBH3 gene promoter region (Fig. 2b). The DNA re-
gion assayed, labelled R in Fig. 2b, includes three CpG
a
b
Fig. 2 The ALKBH3 gene promoter region. a The ALKBH3 gene promoter is transcriptionally active in variant human mammary epithelial cells
(vHMEC) based on available data from the Roadmap Epigenetic Consortium (Roadmap Epigenomics Consortium, Nature 2015). Data for vHMEC
are shown here for markers associated with active transcription (H3K4me3 and H3K36me3) together with repressive markers (H3K27me3, H3K9me3,
H3K4me1 and 5-methylcytosine (DNA methyl)). Additionally, DNAse and RNA sequencing results from vHMEC cells are shown – reflecting chromatin
accessibility and mRNA expression, respectively. b The ALKBH3 gene promoter region is shown with respect to the FANTOM5 transcription start site
(TSS) as arrows p1 and p2 along with the 1st exon and the promoter-associated CpG island (UCSC defined). The CpG methylation assay for ALKBH3
was designed to include CpG sites proximal to the TSS and the regions selected is indicated by a black box (labelled R) covering three closely spaced
CpG dinucleotides found -50, −53 and -58 bp upstream of the major TSS (p1 region in FANTOM5). Additionally, the region where statistically significant
associations were revealed between CpG methylation and loss of expression for the ALKBH3 gene in tumors is marked out and labelled for expression
as “Xprs” (see further information in Additional file 1)
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sites found −50, −53 and -58 bp upstream of the major
TSS (FANTOM5 element p1). In this way, the assay was
designed to reflect ALKBH3 promoter methylation sta-
tus which we then applied across 303 DNA samples, i.e.
8 breast-derived cell lines, 30 normal breast tissue sam-
ples and 265 primary breast tumors.
ALKBH3 epigenetic repression found in two breast cancer
cell lines
Out of the eight breast-derived cell lines analysed with
respect to ALKBH3 promoter methylation, seven were
derived from breast tumors (CAMA-1, Bt-474, HCC-38,
SKBr-3, MDA-MB-231, MCF-7, MDA-MB-468) and one
was derived from a fibrocystic breast lesion (MCF-10A).
We identified ALKBH3 promoter methylation in two of
the seven breast cancer cell lines, i.e. in CAMA-1 and
Bt-474 (Fig. 3a). The MCF10A cell line, often used to re-
flect normal breast epithelial cells, was clearly unmethy-
lated over the ALKBH3 promoter.
ALKBH3 mRNA expression was not detected in either
CAMA-1 or Bt-474 whereas all other cell lines showed
ALKBH3 mRNA expression (Fig. 3b). The association
between ALKBH3 promoter methylation and mRNA ex-
pression was found to be statistically significant (Spear-
man’s rho = −0.73; P = 0.039). Further, complete loss of
ALKBH3 protein expression was seen only in the two
cell lines showing ALKBH3 promoter methylation, i.e.
CAMA-1 and Bt-474 (Fig. 3c).
ALKBH3 has been reported to catalyse the removal of
3-methylcytosine (3meC) on single stranded DNA [29].
In line with that, RNAi mediated knockdown of
ALKBH3 has previously been shown to cause an in-
crease in 3meC levels on single-stranded DNA [30]. To
determine the functional impact of ALKHB3 promoter
methylation, we developed a novel imaging-based assay
for the quantification of 3meC on single stranded DNA.
Using this method we confirmed previous findings [30]
demonstrating increased formation of 3meC damage fol-
lowing siRNA knock-down of ALKBH3 (Additional file 2).
Further, we show statistically significant differences in
3meC damages between ALKBH3 deficient cell line
CAMA-1 compared with ALKBH3 expressing cell line
MDA-MB-468 (P = 0.029), see Fig. 3d and e. For refer-
ence, we show that 5meC intensities are not significantly
different between CAMA-1 and MDA-MB-468 (P = 0.69).
This indicates that, comparable to knockdown of
ALKBH3 [30], epigenetic inactivation of ALKBH3 results
in a higher burden of 3meC, most likely because of less ef-
ficient repair of alkylation damage.
CpG promoter methylation and expression of the ALKBH3
gene in normal and primary breast tumor samples
Out of the 265 primary tumors analysed with respect to
ALKBH3 promoter methylation, a subset of 30 tumor
samples were matched with adjacent normal breast tis-
sue samples from the same patients – thereby enabling
assessment of differential methylation in paired samples.
This analysis reveals clear differences in CpG methyla-
tion over the ALKBH3 promoter region between pri-
mary tumors and normal breast tissue from the same 30
individuals (Fig. 4a).
This analysis further shows that, in normal breast tissue,
the mean methylation levels over the ALKBH3 promoter
region is approximately 1.0% (99%CI: 0.12–1.9%). Devia-
tions from the 99% confidence interval for ALKBH3 pro-
moter methylation levels in normal breast tissue samples
can be considered “aberrant”. On the basis of the upper
99%CI for normal breast tissue samples (99%CI upper
limit ~2% methylation), the incidence of ALKBH3 pro-
moter methylation in primary breast tumors is approxi-
mately 27%, i.e. 72 out of 265 primary breast tumors show
aberrant ALKBH3 promoter methylation.
RNA samples available from normal breast tissue and
tumor samples were used to assess ALKBH3 mRNA ex-
pression. Firstly, this analysis demonstrates statistically
significant differences in ALKBH3 mRNA expression be-
tween normal breast tissue and tumor samples wherein
breast tumors generally show reduced ALKBH3 expres-
sion (Fig. 4b). This provides an independent confirm-
ation for the previous observations based on the use of
available data from the TCGA project shown in Fig. 1b.
Secondly, by using DNA samples available from a subset
of the same tumor samples as analysed with respect to
ALKBH3 expression, we were able to assess the associ-
ation between mRNA expression levels and promoter
methylation status. This analysis, shown in Fig. 4c, fur-
ther validates the impact of ALKBH3 promoter methyla-
tion on mRNA expression levels.
ALKBH3 promoter methylation with respect to clinical
relevance
Table 1 displays clinical and pathological characteristics of
the patient cohort (n = 265). ALKBH3 promoter methyla-
tion was not found to be significantly associated with the
expression of subtype-specific markers, i.e. estrogen-
receptor (ER), progesterone-receptor (PR), erb-b2 recep-
tor tyrosine kinase 2 (known as HER2) and MKI67
(known as Ki-67) as shown in Fig. 5a. Additionally, no as-
sociations were found for ALKBH3 promoter methylation
in relation to discrete subtype classification based on these
four subtype-specific markers, histological grade, tumor
size or nodal status (Additional file 3).
Nonetheless, we found significantly reduced survival
in patients with tumors showing ALKBH3 promoter
methylation (Fig. 5b). This was seen in breast tumors
with high cytosine methylation levels over the ALKBH3
promoter region, i.e. those showing at least 20% cytosine
methylation (Fig. 5b). This level of methylation is indeed
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substantially higher than the 2% threshold level defining
aberrant CpG methylation as was established by looking
at the distribution seen in normal breast tissue samples
(see section 3.4).
The incidence of clinically relevant ALKBH3 methy-
lation (thresholding at the 20% cytosine methylation
level) is approximately 5% in our cohort (13 of 265;
4.9%) and, on the basis of Cox’s proportional hazards
regression analysis, we found that these patients were
at approximately 2.3-fold increased risk of death result-
ing from breast cancer in a multivariate model includ-
ing adjustment for age and year at diagnosis (HR = 2.3;
P = 0.012).
Discussion
ALKBH3 repression by epigenetic mechanisms in breast
cancer
In this study, we show that the ALKBH3 gene promoter
region undergoes aberrant epigenetic repression in a sig-
nificant proportion of primary breast tumours. The
ALKBH3 gene is therefore a novel addition to the cata-
logue of DNA repair genes found inactivated in breast
cancer. Previous studies have shown that treatment with
the DNA alkylating agent MMS induces the expression
of ALKBH3, highlighting the important role of ALKBH3
in repair of alkylation DNA damage [21]. Indeed, our re-
sults indicate that inactivation of ALKBH3 is associated
a d
e
b
c
Fig. 3 Epigenetic silencing of ALKBH3 and accumulation of 3-methylcytosine damage. a CpG methylation analysis for the ALKBH3 gene promoter
by pyrosequencing and (b) ALKBH3 mRNA expression analysis by qPCR in breast cancer cell lines (CAMA1, Bt-474, HCC-38, SKBr-3, MDA-MB-231,
MCF-7 and MDA-MB-468) and a mammary epithelial cell line derived from a fibrocystic lesion of the breast (MCF10A). The association between
ALKBH3 promoter methylation and mRNA expression was found to be statistically significant (Spearman’s rho = −0.73; P = 0.039). c ALKBH3 protein
expression analysed by western blotting using the same panel of breast-derived cell lines revealing lack of expression in two cell lines (CAMA-1 and Bt-
474). Actin protein expression is shown for comparison. d Immunofluorescent staining for 3-methylcytosine and 5-methylcytosine in CAMA-1 (ALKBH3
methylated) and MDA-MB-468 (ALKBH3 unmethylated). The P-value shown was derived from Wilcoxon’s rank sum testing for differences between
CAMA-1 and MDA-MB-468 with respect to intensity for 3-methylcytosine. As expected, no statistically significant differences were found with respect
to overall 5-methylcytosine intensity levels between CAMA-1 and MDA-MB-468. e Representative images showing 3-methylcytosine (green)
and 5-methylcytosine (red) fluorescence staining in CAMA-1 and MDA-MB-468
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with an increased burden of unrepaired alkylation DNA
damage involving 3-methylcytosine (3meC) suggesting
that our findings has biological consequences. If left unre-
paired these modifications can lead to alkylation-induced
cell death or can be converted into mutations through the
use of error-prone translesion DNA polymerases such as
Pol η (eta), Pol ι (iota), and Pol κ (kappa) [31, 32]. Collect-
ively, our observations support the hypothesis that defect-
ive repair of alkylation damage occurs in the development
of a substantial fraction of breast cancers.
Our results furthermore emphasize the importance of
quantification-based methods for DNA methylation ana-
lyses in clinical applications. This becomes clear by look-
ing at varied levels of CpG methylation over the ALKBH3
promoter with respect to survival outcomes. Here,
increasingly higher levels of promoter methylation were
associated with shortened patient survival. Declaring tu-
mours as either ALKBH3 promoter methylated or
unmethylated is therefore not a straightforward task. In
this study, two different methods are applied for this pur-
pose, i.e. 1) making use of normal tissue samples as refer-
ence to then define “abnormally” high levels of ALKBH3
promoter methylation in tumours and 2) by identifying
clinically relevant levels of ALKBH3 promoter methyla-
tion. Making use of normal breast samples as a reference,
does not necessarily provide a means to identify tumours
showing ALKBH3 inactivation events. This is because
only slightly elevated, but still “abnormal”, promoter
methylation might simply reflect passenger events of no
relevance to the course of disease progression. The second
a
b c
Fig. 4 ALKBH3 promoter methylation in primary breast tumors and adjacent normal breast tissue. a Differential CpG methylation over the
ALKBH3 promoter is observed in a subset of primary breast tumors. The tumor (T; red coloured bars) and normal breast tissue (N; grey coloured
bars) samples are matched, i.e. derived from the same individual and arranged side-by-side on the x-axis with ALKBH3 promoter methylation for
each sample represented as a bar. The standard deviation is shown (line extensions from the bars). The P-value shown was derived from a paired
Wilcoxon’s hypothesis test (P = 0.00012). b Box and whisker plot of ALKBH3 mRNA expression in normal breast tissue samples and primary breast
tumors. The P-value shown was derived from a Wilcoxon’s hypothesis test (P = 0.014). c ALKBH3 promoter methylation data plotted on x-axis and
mRNA expression data on y-axis for primary breast tumors. The P-value shown was derived from Spearman’s correlation testing (Spearman’s
rho = −0.577; P = 0.024)
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method refers to making use of clinical parameters involv-
ing tumour phenotype or disease survival to then declare
a “clinically relevant” threshold for defining ALKBH3 pro-
moter methylated tumours. Given the observed impact on
disease progression, this second method is more likely to
hold relevant at least as a proxy for identifying tumours
affected by ALKBH3 promoter methylation. Using this
definition, we report the incidence of ALKBH3 promoter
methylation at approximately 5% in our cohort (13 out of
265 primary breast cancers).
DNA repair deficiency in breast cancer
Defective DNA repair capacity is frequently observed in
various human cancers [14]. In breast cancer, this mostly
Table 1 Clinical and pathological characteristics of the patient cohort
Positive Negative
Estrogen-Receptor 175 (72%) 68 (28%)
Progestrone-Receptor 136 (56%) 108 (44%)
HER2-positive (over-expressed) 20 (14%) 121 (86%)
Ki67-positive (>14% positivity) 84 (60%) 55 (40%)
1986–1991 1991–1996 1996–2001 2001–2004
Year of Diagnosis 81 (30%) 121 (46%) 60 (23%) 3 (1%)
26–42 42–58 58–74 74–91
Age at Diagnosis 36 (14%) 104 (39%) 80 (30%) 45 (17%)
5–30 30–55 55–80 80–100
Tumour size (mm) 94 (77%) 24 (20%) 1 (1%) 3 (2%)
Nodal status 112 (64%) 63 (36%)
+ ++ +++
Histological Grade 19 (13%) 62 (41%) 69 (46%)
Fig. 5 ALKBH3 promoter methylation with respect to clinical parameters and breast cancer-specific survival. a ALKBH3 promoter methylation analysed
with respect to clinical and subtype-specific markers: estrogen-receptor, progesterone-receptor, HER-2 over-expression and Ki-67. The P-values shown
were derived from Wilcoxon’s hypothesis testing. b ALKBH3 promoter methylation analysed with respect to patient survival (breast cancer-specific
survival). The analyses shown were carried out using increasingly higher threshold levels for ALKBH3 promoter methylation as indicated. The P-values
were derived from log-rank hypothesis testing for differences in survival outcomes
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involves defective repair of DNA double-stranded breaks
by homologous recombination (HR), e.g. as is known to
occur in tumor cells arising in carriers of either BRCA1
or BRCA2 germline mutations [33]. Other potential
sources of DNA repair deficiency in breast cancer, also
involving DSB repair processes, include germline muta-
tions in DNA repair genes PALB2, FANCM, ATM,
CHEK2 (and possibly also RAD51C) characterized as
loss-of-function variants [27, 34, 35]. Additionally, som-
atic mutations occur in both BRCA1 and BRCA2 as well
as the ATM gene accounting for a small fraction of pa-
tients [27].
In addition to genetic mutations, our previous studies
along with others have shown that the BRCA1 gene
undergoes CpG promoter methylation in at least 5–10%
of all sporadically arising breast tumors [6]. More re-
cently, RAD51C (a RAD51 paralog involved in double-
strand break repair) and the RAD51 recombinase have
been identified as targets of epigenetic silencing in breast
cancer [8, 36, 37]. Other contributors include deregu-
lated expression of miRNAs including miR-182 and
miR-146a/b targeting BRCA1 mRNA transcripts for deg-
radation [38, 39].
In summary, the development of breast cancer is
clearly linked to inactivation of genes involved in the re-
pair of DNA double-stranded breaks by HR. The in-
volvement of other DNA repair pathways in breast
cancer development is, however, currently unclear. Of
these, DNA repair of alkylation damage by direct rever-
sal has been suggested following the identification of
CpG promoter methylation of the MGMT gene in breast
cancer [17]. Our results support this notion by identify-
ing the ALKBH3 gene as a novel addition to the cata-
logue of DNA repair genes found inactivated in breast
cancer.
The functional consequences of ALKBH3 epigenetic
silencing
According to our results, ALKBH3 represents a candi-
date tumor suppressor gene. A high burden of muta-
tions, caused by ineffective DNA repair, is generally
accepted as an important factor in cancer development.
Incomplete removal of alkyl groups on DNA has been
shown to cause DNA damage, cell cycle arrest and apop-
tosis. Indeed, cancer genome sequencing has already
established an important role for alkylation damage lead-
ing to genetic mutations [20]. Consequently, it seems
likely that ALKBH3 mediates its tumor suppressive
function via its role in DNA alkylation repair. This is
supported by the increased level of alkylation damage in
ALKBH3 inactivated cells, reported here and in previous
studies [30]. It can, however, not be ruled out that other
described functions of ALKBH3 also contribute to its
anti-tumor activities – including alkylation repair of
RNA and the recently described link to regulation of 1-
methyladenine mark in mRNA [29, 40–42].
While our data suggest that ALKBH3 has tumor sup-
pressor properties in breast cancer, other research has
shown ALKBH3 overexpression in various cancer types.
ALKBH3 overexpression is found in prostate cancer [43]
and other cancer types [44–48]. In this context,
ALKBH3 overexpression likely relates to adaptation of
cancer cells to tolerate endogenous alkylation damage to
DNA or RNA. This interpretation is in fact relevant in
the context of a recent pre-clinical study showing resist-
ance to alkylating drug temozolomide following experi-
mental overexpression of MGMT [49]. Similar results
have also been described with respect to ALKBH2 [50].
Defective repair of alkylation damage and precision
medicine
Precision medicine is aimed at optimizing treatment bene-
fits by looking at each patient in terms of genomic or epi-
genomic variants and, on the basis of this information, to
then select the most appropriate combination of cytotoxic
or targeted drugs. This is highly relevant with respect to
CpG promoter methylation of the MGMT gene now
widely recognized as a predictor for patient response to al-
kylating agents such as temozolomide [19, 51]. Indeed,
temozolomide induces methylation damage in DNA in-
volving O6-methylguanine along with N7-methylguanine.
In this way, tumor cells lacking the MGMT repair gene as
a result of CpG promoter methylation events are highly
sensitive to temozolomide [19]. Similarly, in breast cancer,
loss of MGMT was recently linked to temozolomide sen-
sitivity in a pre-clinical study [49]. Whether the same
principle can be applied with respect to the ALKBH3
gene, i.e. by inducing 3meC and 1meA in patients having
developed breast tumors with ALKBH3 promoter methy-
lation, remains to be determined.
Conclusions
We propose here that the ALKBH3 gene is a novel
addition to the catalogue of DNA repair genes found
inactivated in breast cancer. The value of ALKBH3 pro-
moter methylation as a prognostic marker was revealed
through quantification of CpG methylation levels by py-
rosequencing. In this way, our results emphasize the use
of quantification-based methods for the assessment of
CpG methylation marks in clinical applications. In our
cohort, clinically relevant ALKBH3 promoter methyla-
tion occurs in at least 5% of all breast cancers and, al-
though independent cohorts will be needed for
confirmation, this event appears to be associated with
highly aggressive disease behaviour. These observations
underscore defective repair of alkylation damage occur-
ring in the development of breast cancer.
Stefansson et al. BMC Cancer  (2017) 17:469 Page 11 of 13
Additional files
Additional file 1: The relation between CpG methylation and expression
for the ALKBH3 gene shown here based on available data from the Cancer
Genome Atlas project. This catalogue includes only CpG’s found differentially
methylated between breast cancers and normal breast tissue samples. The
table lists out statistically significant CpG’s with rho < −0.30 and at least two-
fold change in expression between unmethylated and methylated tumours.
(XLSX 10 kb)
Additional file 2: RNAi for ALKBH3 analysed with respect to 3-methyl-
cytosine immunostaining. A) U2OS cells were transfected with a control
(scrambled siRNA) and ALKBH3 siRNA for 72 h. After fixation cells were
denatured in 1.5 M HCL for 30 min (to gain access to single stranded
DNA) and immunostained for 3-me-C and 5-me-C. As expected, decreased
ALKBH3 expression resulted in increased accumulation of 3-me-C, indicating
less efficient repair, without any detectable changes in 5-me-C levels. B)
Quantification of at least 100 cells reveals approximately 1, 6-fold differences
in 3-me-C damages based on nuclear intensity measured using CellProfiler.
The fold differences are computed as the average signal derived form
ALKBH3 siRNA treated cells divided by the average signal derived from
scrambled siRNA treated cells (by default set to one in the figure). 3-me-
C = 3-methyl-cytosine, 5-me-C = 5-methyl-cytosine. (TIFF 3866 kb)
Additional file 3: ALKBH3 methylation analysed with respect to
prognostic parameters (breast cancer subtype, histological grade, tumour
size and nodal status). (XLSX 12 kb)
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